Zhejiang Wolwo Bio-Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 9.91%

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) has an Asset Resilience Ratio of 9.91% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) strategic asset index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CN¥286.82 Million
≈ $41.97 Million USD Cash + Short-term Investments

Total Assets

CN¥2.89 Billion
≈ $423.37 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2014–2024)

This chart shows how Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See 300357 net asset quality score to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 300357 market cap.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥286.82 Million 9.91%
Total Liquid Assets CN¥286.82 Million 9.91%

Asset Resilience Insights

  • Limited Liquidity: Zhejiang Wolwo Bio-Pharmaceutical Co Ltd maintains only 9.91% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
AstraZeneca PLC
F:ZEGA
Drug Manufacturers - General 0.03%
AstraZeneca PLC
NASDAQ:AZN
Drug Manufacturers - General 0.10%
Novartis AG
SW:NOVN
Drug Manufacturers - General 0.08%
Pfizer Inc
SA:PFIZ34
Drug Manufacturers - General 5.48%
Pfizer Inc
NYSE:PFE
Drug Manufacturers - General 5.48%
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
SHE:301096
Drug Manufacturers - General 1.58%
Hunan Jingfeng Pharmaceutical
SHE:000908
Drug Manufacturers - General 0.38%
Zhejiang Int'L Group Co Ltd
SHE:000411
Drug Manufacturers - General 0.00%

Annual Asset Resilience Ratio for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (2014–2024)

The table below shows the annual Asset Resilience Ratio data for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 7.24% CN¥196.09 Million
≈ $28.69 Million
CN¥2.71 Billion
≈ $396.43 Million
+2.66pp
2023-12-31 4.58% CN¥117.39 Million
≈ $17.18 Million
CN¥2.56 Billion
≈ $374.93 Million
-8.84pp
2022-12-31 13.42% CN¥295.05 Million
≈ $43.18 Million
CN¥2.20 Billion
≈ $321.62 Million
-5.78pp
2021-12-31 19.20% CN¥370.93 Million
≈ $54.28 Million
CN¥1.93 Billion
≈ $282.71 Million
+0.07pp
2020-12-31 19.13% CN¥307.03 Million
≈ $44.93 Million
CN¥1.60 Billion
≈ $234.83 Million
+16.24pp
2019-12-31 2.90% CN¥41.37 Million
≈ $6.05 Million
CN¥1.43 Billion
≈ $208.99 Million
-8.07pp
2018-12-31 10.97% CN¥116.00 Million
≈ $16.97 Million
CN¥1.06 Billion
≈ $154.80 Million
-24.40pp
2017-12-31 35.36% CN¥300.00 Million
≈ $43.90 Million
CN¥848.31 Million
≈ $124.13 Million
+10.83pp
2016-12-31 24.54% CN¥171.00 Million
≈ $25.02 Million
CN¥696.89 Million
≈ $101.98 Million
+8.18pp
2015-12-31 16.35% CN¥100.00 Million
≈ $14.63 Million
CN¥611.49 Million
≈ $89.48 Million
+5.06pp
2014-12-31 11.29% CN¥60.00 Million
≈ $8.78 Million
CN¥531.31 Million
≈ $77.75 Million
--
pp = percentage points

About Zhejiang Wolwo Bio-Pharmaceutical Co Ltd

SHE:300357 China Drug Manufacturers - General
Market Cap
$1.63 Billion
CN¥11.13 Billion CNY
Market Cap Rank
#7048 Global
#1600 in China
Share Price
CN¥21.25
Change (1 day)
+1.53%
52-Week Range
CN¥19.91 - CN¥35.30
All Time High
CN¥5101.55
About

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceutical products for the diagnosis and treatment of allergic diseases in China and internationally. The company offers Changdi, a dust mine drops; Changhao, an artemisia annua pollen allergen sublingual drops; and Changdian, a dust mite skin prick diagnost… Read more